Skip to content
Review Open access

Interkingdom microbiome physiology in colorectal cancer: barrier dysfunction, immune-metabolic signaling, and therapeutic resistance

Sep 2026 · Frontiers in Physiology · Vol 17 · 0 citations · 155 references
Medicine

TL;DR

This review synthesizes evidence linking the bacteriome, mycobiome, and phageome to colorectal carcinogenesis, immune modulation, metabolic signaling, and therapeutic response and proposes that therapeutic resistance may sometimes reflect a treatment-selected ecological state rather than the action of a single resistance-conferring microbe.

Abstract

Colorectal cancer develops within a physiologically altered intestinal ecosystem. Epithelial barrier disruption, chronic inflammatory signaling, immune remodeling, and metabolic rewiring reshape host-microbial interactions in this niche. Although most colorectal cancer microbiome reviews have emphasized bacterial taxa, the gut ecosystem is inherently multi-kingdom, comprising bacteria, fungi, bacteriophages, and other viral elements that interact with one another and with the host. In this review, we propose that the clinically relevant unit of the colorectal cancer microbiome is often not a single organism but a configured interkingdom whose functional output depends on local physiology. Throughout, we distinguish human observational associations from mechanisms demonstrated in experimental models and from prospectively validated clinical effects. We synthesize evidence linking the bacteriome, mycobiome, and phageome to colorectal carcinogenesis, immune modulation, metabolic signaling, and therapeutic response. We highlight context-dependent mechanisms, including the paradoxical effects of Fusobacterium nucleatum, fungal regulation of myeloid and inflammasome pathways, phage-mediated control of bacterial virulence, and cross-kingdom metabolic circuits involving butyrate, succinate, bile acids, lactate, and arginine. We further propose, as a conceptual framework requiring longitudinal validation, that therapeutic resistance may sometimes reflect a treatment-selected ecological state rather than the action of a single resistance-conferring microbe. Finally, we address the reproducibility challenges raised by low-biomass intratumoral microbiome studies and outline minimum methodological standards for future multi-kingdom investigations. A framework centered in physiology, attentive to contamination, and organized around interactions may improve biomarker development and support rational microbiome-directed strategies in colorectal cancer.

Read PDF

Similar papers

Review Open access Oct 2026

The Gut Microbiota–Immunity Axis in Colorectal Cancer: Implications for Immunotherapy and Clinical Translation

This review critically examines emerging microbiome-directed strategies, including fecal microbiota transplantation, next-generation probiotics, defined bacterial consortia, dietary and perioperative interventions, postbiotics, and bacteriophage-based approaches, as potential means of modifying immune resistance in MSS...

Izabela Siemińska · 0 citations
Review Open access Sep 2026

Gut microbiota-mediated chemotherapy resistance in colorectal cancer: mechanisms and precision interventions

Colorectal cancer (CRC) is a major global health burden, and chemotherapy resistance remains a major challenge to effective treatment. Increasing evidence indicates that the gut microbiota may contribute to variability in chemotherapy response in CRC through microbial metabolism, tumor-cell adaptation, immune regulatio...

Yan Li, Fang-Rui Wang, Tao Li et al. · 0 citations
Review Oct 2026

Cancer and the microbiome: from association to intervention.

Current evidence linking the intestinal microbiome to anticancer therapy outcomes is synthesised, strategies and challenges for therapeutic modulation of the microbiome are evaluated, and emerging insights into the mycobiome are introduced.

A. Moradi, R. Winayak, S. Pal · 0 citations
Review Open access Sep 2026

Microbial Signals in Cancer: Dissecting Host–Microbiota–Tumor Interactions and Potential Therapeutic Strategy

Cancers develop within a host ecosystem in which kinds of factors such as gut and tumor‐resident microbiota influence the tumor microenvironment (TME) and therapeutic response. High‐throughput sequencing has revealed the presence of low‐biomass bacteria, fungi, and viruses across diverse malignancies, establishing the...

Juan Lu, Meng-Juan Xuan, Liang Yu et al. · 0 citations
Review Open access Oct 2026

Microbiota–host crosstalk in ulcerative colitis: mechanistic evidence and translational prospects for traditional Chinese medicine

Ulcerative colitis (UC) is sustained by reciprocal interactions among intestinal dysbiosis, altered microbial metabolism, epithelial barrier dysfunction, and mucosal immune activation. This narrative review examines that microbiota–metabolism–barrier–immune network and evaluates how traditional Chinese medicine (TCM) m...

Jing Chen, Jing Du, Bao-Xi Mu et al. · 0 citations
Open access Aug 2026

THE ROLE OF THE GUT MICROBIOME IN THE DEVELOPMENT AND PROGRESSION OF GASTROINTESTINAL DISEASES: CURRENT EVIDENCE AND FUTURE PERSPECTIVES

The gut microbiome is emerging as an important component of modern gastroenterology, with considerable potential for improving disease prevention, diagnosis, prognosis, and treatment.

Ulykbek Daurenov, Dana Suyunbay, Alua Toqseiıt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.